IMRX - Immuneering Corporation
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
IMRX price evolution
IMRX
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $55.26 | $63.69 | $74.45 | $89.08 |
| Long term investments | ||||
| Property, plant & equipment | $4.95 | $5.12 | $5.25 | $5.4 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $68.56 | $77.09 | $87.98 | $102.58 |
| Current liabilities | ||||
| Accounts payable | $1.94 | $2.62 | $2.27 | $2.11 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $6.92 | $6.78 | $5.18 | $7.85 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $10.84 | $10.78 | $9.26 | $12.01 |
| Shareholders' equity | ||||
| Retained earnings | -$206.24 | -$191.65 | -$177.57 | -$163.26 |
| Other shareholder equity | $0.01 | -$0 | -$0 | |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.01 | $0.25 | $0.5 | |
| Inventory | ||||
| Total current assets | $89.08 | $108.75 | $152.33 | $37.73 |
| Long term investments | ||||
| Property, plant & equipment | $5.4 | $5.78 | $6.13 | $0.68 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $102.58 | $122.37 | $166.7 | $38.42 |
| Current liabilities | ||||
| Accounts payable | $2.11 | $3.15 | $1.39 | $1.48 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $7.85 | $8.05 | $5.63 | $2.26 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $12.01 | $12.52 | $10.72 | $2.8 |
| Shareholders' equity | ||||
| Retained earnings | -$163.26 | -$109.79 | -$59.27 | -$25.74 |
| Other shareholder equity | -$0 | -$0.03 | -$0.05 | |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $16.3 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.75 | |||
| Net income | ||||
| Net income | -$15.08 | |||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.32 | $2.08 | $2.31 | |
| Cost of revenue | ||||
| Gross Profit | $0.16 | $0.93 | $1.03 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $58.41 | $51.9 | $34.81 | $18.11 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.31 | |||
| Interest expense | $3.61 | $1.01 | $0.17 | $0.04 |
| Net income | ||||
| Net income | -$53.47 | -$50.51 | -$33.54 | -$17.04 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $20.94 | $26.36 | $21.39 | $7.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $5.34 | $0.98 | $0.98 | $28.44 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$14.2 | $0.32 | $6.88 | -$13.23 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $7.3 | $41.83 | -$75.62 | -$0.05 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $28.44 | $0.02 | $144.26 | $37.98 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$13.23 | -$2.25 | $37.8 | $23.31 |
News
Fundamentals
| Market cap | $205.55M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 31.05M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.99 |
| Quick ratio | N/A |